115
Participants
Start Date
December 31, 2005
Primary Completion Date
December 31, 2008
Study Completion Date
September 30, 2009
BMS-663513
mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
Hillman Cancer Center, Pittsburgh
Local Institution, Bordeaux
Local Institution, Saint-Herblain
Indiana University Cancer Center, Indianapolis
Local Institution, Paris
Local Institution, Paris
City Of Hope National Medical Center, Duarte
Local Institution, Villejuif
Yale University School Of Medicine, New Haven
Beth Israel Deaconess Medical Center, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Local Institution, Toronto
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY